Exscientia Ltd: against COVID-19 Company
Entity: Exscientia
Category: AI for Drug Discovery
Description: Exscientia is applying AI and big data processing to accelerate drug discovery and development.
Project: Treatment for Covid-19.
Summary: Oxford firm Exscientia, who specialise in Artificial Intelligence-driven drug discovery have teamed up with Calibr, a UK national science facility, in order to screen more than 15,000 drugs for their effectiveness as a treatment for Covid-19. Beginning by screening Calbr’s collection for existing compounds that could be repurposed to fight COVID-19, they also plan to use their AI to design even more effective compounds.
Category: AI for Drug Discovery
Description: Exscientia is applying AI and big data processing to accelerate drug discovery and development.
Project: Treatment for Covid-19.
Summary: Oxford firm Exscientia, who specialise in Artificial Intelligence-driven drug discovery have teamed up with Calibr, a UK national science facility, in order to screen more than 15,000 drugs for their effectiveness as a treatment for Covid-19. Beginning by screening Calbr’s collection for existing compounds that could be repurposed to fight COVID-19, they also plan to use their AI to design even more effective compounds.
Technology:
AI for Drug Discovery
Headquarters:
United Kingdom
Founded Date:
2012
Employees Number:
11-50
Funding Status:
Early Stage Venture
Register and Claim Ownership